Tandem Diabetes Care on the brink of a turnaround - pharmacy strategy expected to accelerate growth from 2027!
Reading Time: 2 minutes
The medical technology company Tandem Diabetes Care (TNDM) already supplies two leading insulin pumps for type 1 diabetics aged 2 and above with the t:slim X2 and the smaller smartphone-controlled Tandem Mobi. The associated Control-IQ+ technology supports automated insulin management (AID) with algorithms. More than 500,000 users in 25 countries are already being served. Now, a transformation process aimed at a stronger focus on sales through the pharmacy channel is set to accelerate revenue and profitability starting in 2027. Through the traditional...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
